Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 1

Status

Recruiting 2Completed 2Active not recruiting 2Available 1

Sponsor Class

INDUSTRY 7OTHER 5NETWORK 1

Study Type

Interventional 5Observational 1Expanded_access 1

Sponsor

Cancer Type

Lymphoid 7Other hematologic neoplasm 2

Conditions

Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Lymphoma 1Leukemia 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × tisagenlecleucel × 1 year × Clear all
NCT03876769 2026-06-02

CASSIOPEIA

Novartis

Phase 2 Active not recruiting
121 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

NCT06785818 2026-05-05

Long-term Follow up Local Registry Study of Kymriah in South Korea

Novartis

Recruiting
500 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03601442 2026-04-23

Managed Access Programs for CTL019, Tisagenlecleucel

Novartis

Available
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT04094311 2026-04-20

Study of Out of Specification for Tisagenlecleucel

Novartis

Phase 3 Recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05888493 2026-04-17

LEDA

Novartis

Phase 3 Active not recruiting
109 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

NCT05075603 2025-10-23

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

NeoImmuneTech

Phase 1 Completed
17 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03568461 2025-10-07

ELARA

Novartis

Phase 2 Completed
98 enrolled 9 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡